IL1B and pulmonary arterial hypertension: As shown in Figure 3I, ETRQβ-002 treatment effectively reduced mRNA expression of classical proinflammatory cytokines including IL-1β, IL-6, monocyte chemoattractant protein 1, and tumor necrosis factor α, some of which were significantly increased in patients with PAH (23, 24).